How Technology Is Accelerating Site Activation: Examples From Novartis And IQVIA

By Rosemary Shirey, IQVIA Technologies

Clinical trial start-up timelines have slowed in recent years, and pharmaceutical sponsors need solutions to help sites get activated more quickly and consistently around the world. They need leading-edge tools that make activation tasks and communication easier for sites. Increasingly, companies are looking for comprehensive solutions that mitigate the driving forces behind delayed study launches without burdening sites with disconnected technologies. Of course, technology must be supported by a strong organization and processes. As protocols and studies become more complex, offering sites in-depth expertise and guidance to keep moving forward is more important than ever.

In the recent webinar, Practical Approaches to Faster Study Start-ups: Making Progress in the Face of Industry Headwinds, industry leaders from Novartis Pharmaceuticals and IQVIA R&D Solutions (RDS) explained how they use innovation from IQVIA Technologies (formerly DrugDev) to accelerate site activation. They discussed how to keep sites organized and on track, how Novartis uses technology to empower sites, and how companies can accelerate study start-up timelines despite industry trends.